UNC HEALTH CARE

MEMORANDUM #127

TO: UNC Hospitals Attending Physicians, Housestaff, Nursing Coordinators, Department Heads and Supervisors

FROM: Catherine Hammett-Stabler, Ph.D., Director, Core Laboratory

Stephanie Mathews, M.D., Director, Analytical Hematology/Urinalysis

Herbert C. Whinna, M.D., Ph.D., Medical Director, McLendon Clinical Laboratories

SUBJECT: Discontinuation of Clinitest® Tablets and Qualitative Urine Microalbumin Testing.

DATE: April 6, 2016

Effective April 15, 2016, the Core Laboratory will discontinue both the use of Clinitest® tablets for the detection of reducing substances in both urine and stool, and Qualitative Urine Microalbumin testing.

Bayer Healthcare ceased to manufacture and distribute the Clinitest® reagents in late 2015. There is no replacement. The reagents were used primarily for pediatric testing when the presence of non-glucose reducing substances was suspected as a result of an inherited carbohydrate metabolic disorder; however, its poor specificity and improvements in newborn screening have made it obsolete.

In place of qualitative urine microalbumin testing, the test urine albumin/creatinine ratio should be ordered.

If you have any questions related to these changes, please contact the Core Laboratory at 984-974-2361.